During the last session, Passage Bio Inc (NASDAQ:PASG)’s traded shares were 0.8 million, with the beta value of the company hitting 1.48. The 52-week high for the PASG share is $1.79, that puts it down -115.66 from that peak though still a striking 45.78% gain since the share price plummeted to a 52-week low of $0.45. The company’s market capitalization is $51.21M, and the average intraday trading volume over the past 10 days was 1.38 million shares, and the average trade volume was 729.44K shares over the past three months.
Passage Bio Inc (PASG) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. PASG has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Passage Bio Inc (NASDAQ:PASG) trade information
Passage Bio Inc (PASG) registered a -0.12% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.12% in intraday trading to $0.83, hitting a weekly high. The stock’s 5-day price performance is 25.63%, and it has moved by -6.85% in 30 days. Based on these gigs, the overall price performance for the year is -5.82%. The short interest in Passage Bio Inc (NASDAQ:PASG) is 1.64 million shares and it means that shorts have 6.61 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 86.17% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, PASG is trading at a discount of -622.89% off the target high and -622.89% off the low.
Passage Bio Inc (PASG) estimates and forecasts
Statistics show that Passage Bio Inc has outperformed its competitors in share price, compared to the industry in which it operates. Passage Bio Inc (PASG) shares have gone down -9.50% during the last six months, with a year-to-date growth rate more than the industry average at 44.09% against 16.80.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -46.23%. While earnings are projected to return 47.04% in 2025.
PASG Dividends
Passage Bio Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Passage Bio Inc (NASDAQ:PASG)’s Major holders
Passage Bio Inc insiders own 0.49% of total outstanding shares while institutional holders control 59.68%, with the float percentage being 59.98%. ORBIMED ADVISORS LLC is the largest shareholder of the company, while 53.0 institutions own stock in it. As of 2024-06-30, the company held over 10.12 million shares (or 17.9847% of all shares), a total value of $8.04 million in shares.
The next largest institutional holding, with 6.05 million shares, is of VESTAL POINT CAPITAL, LP’s that is approximately 10.7504% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $4.81 million.
